Teleflex Inc. 10-Q Summary: Quarter Ended September 28, 2008
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 28, 2008, and the nine months ended on that date. Teleflex Inc. is a diversified manufacturer of specialty-engineered products serving the medical, aerospace, and commercial industries. The reporting period is significantly influenced by the October 2007 acquisition of Arrow International, Inc. (a critical care provider) and the November 2007 acquisition of Nordisk Aviation Products. The company also divested its GMS businesses (automotive/industrial controls) in late 2007, which are reported as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 28, 2008 | Nine Months Ended Sep 28, 2008 |
|---|---|---|
| Net Revenues | $595.9 million | $1.82 billion |
| Gross Profit | $238.8 million (40.1% margin) | $730.3 million (40.0% margin) |
| Net Income (Continuing Ops) | $42.3 million | $100.2 million |
| Diluted EPS (Continuing Ops) | $1.06 | $2.59 |
| Operating Cash Flow | N/A | $98.1 million |
| Total Debt | $1.58 billion | $1.58 billion |
| Cash and Equivalents | $91.4 million | $91.4 million |
| Net Debt to Total Capital | 52% | 52% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 30% in the quarter and 35% year-to-date compared to 2007. This growth was entirely driven by acquisitions (Arrow and Nordisk). Core business revenues actually declined 4% in the quarter and 2% year-to-date due to lower sales volumes in auxiliary power units and recreational marine products.
- Profitability: Gross profit margins improved significantly to 40.1% (Q3) and 40.0% (YTD) from 33.6% and 35.4% in the prior year, primarily due to the addition of higher-margin Arrow product lines.
- Interest Expense: Interest expense surged to $29.0 million in the quarter (from $9.9 million in 2007) and $91.5 million YTD (from $28.6 million in 2007) due to debt incurred to finance the Arrow acquisition.
- Tax Rate: The effective tax rate dropped to 20.9% in the quarter and 24.2% YTD, compared to 215.9% and 83.8% in the prior year. The prior year rates were inflated by a discrete $90.2 million tax charge related to the repatriation of foreign earnings to fund the Arrow acquisition.
- Discontinued Operations: The company recorded a $2.8 million loss from discontinued operations YTD due to post-closing adjustments and contingency settlements related to the sale of the GMS businesses.
Guidance, Outlook, and Risks
- Restructuring Costs: Management estimates future restructuring charges of $22.0 million to $25.0 million in 2008 and 2009 related to the Arrow integration plan. This includes employee terminations, lease terminations, and distribution agreement costs.
- Regulatory Matters (FDA): The FDA issued a corporate warning letter to Arrow in October 2007 regarding quality system deficiencies. Teleflex is implementing a corrective action plan expected to be completed by the end of 2008. Failure to satisfy the FDA could result in product seizures or injunctions.
- Regulatory Matters (UK Tax): HM Revenue and Customs (HMRC) assessed a UK subsidiary (ATI-UK) approximately $13 million in customs duties and $93 million in VAT. The company is vigorously contesting these assessments. An unfavorable resolution could materially adversely affect the business.
- Liquidity: The company maintains a $355.2 million revolving credit facility. No shares have been repurchased under the $300 million authorization due to debt covenants and cash requirements.
Investor Verification Checklist
- Core Revenue Trends: Verify the sustainability of core revenue declines (-4% Q3, -2% YTD) in the Commercial and Medical segments outside of acquisition impacts.
- Arrow Integration Progress: Monitor the execution of the FDA corrective action plan and the realization of projected synergies against the $22-25 million restructuring cost estimate.
- UK Tax Contingency: Track the status of the HMRC appeal regarding the $106 million total assessment (duties + VAT) against the ATI-UK subsidiary.
- Debt Servicing: Assess the impact of high interest expenses ($91.5 million YTD) on future free cash flow and dividend sustainability.
- Discontinued Operations: Confirm that the $2.8 million loss related to the GMS divestiture is fully resolved and no further adjustments are expected.